European Journal of Pharmaceutics and Biopharmaceutics

Official Journal of the

European Journal of Pharmaceutics and Biopharmaceutics - ISSN 0939-6411
Source Normalized Impact per Paper (SNIP): 1.409 Source Normalized Impact per Paper (SNIP):
SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.
SCImago Journal Rank (SJR): 1.366 SCImago Journal Rank (SJR):
SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.
Impact Factor: 4.159 (2016) Impact Factor:
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
5 Year Impact Factor: 4.506 (2016) Five-Year Impact Factor:
To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
Volumes: Volumes 122-133
Issues: 12 issues
ISSN: 09396411

Personal Subscription

Tax/VAT will be calculated at check-out

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.

Topics covered include for example:

  • Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
  • Aspects of manufacturing process design
  • Biomedical aspects of drug product design
  • Strategies and formulations for controlled drug transport across biological barriers
  • Physicochemical aspects of drug product development
  • Novel excipients for drug product design
  • Drug delivery and controlled release systems for systemic and local applications
  • Nanomaterials for therapeutic and diagnostic purposes
  • Advanced therapy medicinal products
  • Medical devices supporting a distinct pharmacological effect


"The Rules of 3"

The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work:

  1. The paper must report on novel findings that are not merely an unprecedented combination of known aspects in pharmaceutics and biopharmaceutics of major importance.
  2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.
  3. The study described in the manuscript must not merely confirm the state of the art in the field of pharmaceutics and biopharmaceutics, but advance it.